Charles River Laboratories International Community

NYSE:CRL Community

3 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

Charles River Laboratories International

AN

AnalystConsensusTarget

Consensus Narrative from 18 Analysts

Ramp-up Of Noveprim's NHP Supply And Cost Savings Will Improve Future Margins

Key Takeaways Strategic stock buybacks and cost-saving initiatives should boost EPS growth and protect profit margins. Revenue stabilization and efficiencies in key segments, along with diverse supply chain improvements, aim to enhance operational margins and profitability.

US$155.28

FV

26.2% undervalued

0.39%

Revenue growth p.a.

1

0

1

4 days ago